U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 2061 - 2070 of 39119 results

Status:
Investigational
Source:
INN:brallobarbital
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Brallobarbital possessed the sedative and hypnotic properties and was a component of Vesparax that was used to treat sleep disorders. However, was revealed that brallobarbital was responsible for the problems in Vesparax intoxication.
Status:
Investigational
Source:
INN:guaisteine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Guaisteine, a thiazolidine derivative that was used as an antitussive agent. This compound has never been marketed.
CPI-613 is a lipoate derivative synthesized to be catalytically inert but to potentially mimic lipoate catalytic intermediates. The drug is in phase II of clinical trials for the treatment of Myelodysplastic syndromes; Pancreatic cancer; Small cell lung cancer; Solid tumors; Bile duct cancer; Acute Myeloid leukemia. The mechanism of CPI-613 action can be explained by (I) inhibition of tumor cell pyruvate dehydrogenase complex (PDC) through activation of pyruvate dehydrogenase kinases leading to inactivating phosphorylation of the E1alpha-subunit of PDC; and (II) inhibition of alpha-ketoglutarate dehydrogenase.
Status:
Investigational
Source:
NCT00909688: Phase 1 Interventional Completed Healthy
(2009)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

BLI 489 was developed by Wyeth as a 6-methylidene-penem β-lactamase inhibitor for the treatment of bacterial infections and urinary tract infections. BLI-489 has shown the promising clinical data, however, development of this drug, was discontinued.
Status:
Investigational
Source:
INN:mepramidil
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mepramidil (PF-26) is a coronary vasodilator.
Status:
Investigational
Source:
INN:flavodic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Flavodic acid is a synthetic hydrosoluble derivative of natural flavonoids. It has been shown to reduce capiliary fragility and permeability. Sodium flavodate was marketed by the Italian pharmaceutical company Farmaceutici under tradename Pericel.
Status:
Investigational
Source:
INN:devapamil
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

In the early stages of testing was shown that it is about 4 times more potent than gallopamil and 12 times more potent than verapamil in its effects on smooth muscle tone and labeled calcium uptake.
Status:
Investigational
Source:
INN:diniprofylline
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Diniprofylline is a vasodilator, broncholytic agent and respiratory stimulant used in severe respiratory insufficiencies.
Status:
Investigational
Source:
INN:dipiproverine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Dipiproverine is the spasmolytic agent. It was used as anticholinergic drug.
Status:
Investigational
Source:
INN:diprogulic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Diprogulic acid (Dikegulac) is used as a precursor in vitamin C synthesis. It is plant growth regulator for hedges. Dikegulac is used to differentially kill terminal apices, and it analogously inhibits basic metabolic functions in dividing cells, but not stationary cells, in suspension culture. At the lowest concentrations, dikegulac partially suppresses division of the isolated tobacco protoplasts. Higher concentrations are required to produce visual cytoplasmic damage to the protoplasts, which probably first occurs at the level of the plasmalemma, as the vacuoles can be released intact. Later, tonoplast disruption occurs. It does not inhibit mature leaves.

Showing 2061 - 2070 of 39119 results